



13 September 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

Resonance Health Signs MOU with Major US Radiology Chain

13 September 2005: The Resonance Health Group (ASX: RHT) today announced that it has signed a Memorandum of Understanding (MOU) with a major radiology service provider in the United States for a pilot study in preparation for the commercial launch of its MRI-based liver-iron test, FerriScan[®].

Under the proposed arrangement, the US radiology chain will perform the MRI component of the FerriScan test and will be responsible for billing and collection activities. Resonance Health will perform the FerriScan analysis. The parties will collaborate on launch plans and reimbursement strategy. US site activation under this collaboration is expected to commence in the fourth quarter of 2005.

The new partnership complements the continuing supply of FerriScan to US centres participating in clinical programs being conducted by Novartis and the Thalassemia Clinical Research Network.


Dr James Williams, Managing Director of Resonance Health said:

“This partnership marks a major milestone in the global commercialisation of FerriScan with the intent to supply FerriScan through a significant number of US MRI sites. With our forthcoming profile activities, including the American Society of Hematology (ASH) and the American Association for the Study of Liver Disease (AASLD), held in the US during November and December respectively, we are positioned to begin building our US revenue stream. ASH and AASLD will attract more than 20,000 of the US and world’s clinical specialists responsible for managing patients with iron disorders.”

FerriScan represents a breakthrough in the diagnosis and management of iron overload, most prominently in disease states such as thalassemia and hemochromatosis which affect over two million people in the US alone.

FerriScan provides doctors with information that is more accurate and cost effective than a liver biopsy or serum blood markers without the need for an invasive procedure and possible dangerous side effects.

Having too much iron in the body and being unable to get rid of this excess is one of the world’s most common hereditary disorders. The disorders, often collectively termed as ‘Iron Overload’, are generally classified as primary (e.g. hereditary hemochromatosis – HHC) or secondary (e.g. acquired – transfusion related iron overload such as thalassemia). Approximately 11 million people globally, who have ‘clinically significant’ iron loading would benefit from improved diagnosis and management of their condition.



**Further information:
About 'Iron Overload' Conditions**

Hemochromatosis is a genetic disorder that causes iron deposition in the liver and other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period and its non-specific symptoms. Thalassaemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the quantitative measurement of iron levels in the human body.

Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan, its world leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, UK and Europe. Further information about Resonance Health and FerriScan can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

Media and investor relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director T - +61 8 9286 5300 M - 0409 050 519 Email: jamesw@ferriscan.com Mr Glenn Smith Director Marketing & Sales T - +61 8 9286 5300 M – 0411 433 023 Email: glens@ferriscan.com